Apeiron RIA’s Pfizer PFE Stock Holding History

Apeiron RIA’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,391	Closed	-$728	–	201
2022 Q2	$728	Buy	+1,391	New	+$70.9K	0.2%	50

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Apeiron RIA's PFE Position: Q3 2022 in Review

Apeiron RIA sold out of Pfizer (PFE) in Q3 2022, closing a stake of 1,391 shares — an estimated $728 sold.

Apeiron RIA first reported a position in PFE in Q2 2022 and held it in 1 quarter. The position peaked at $728 in Q2 2022. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.

Apeiron RIA reported no remaining Pfizer position as of Q3 2022 after selling out during the quarter.
Apeiron RIA sold 1,391 Pfizer shares in Q3 2022, an estimated $728.
Apeiron RIA first reported a position in Pfizer in Q2 2022 and held it in 1 quarter.
Apeiron RIA's Pfizer position peaked at $728 in Q2 2022.
3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.

Based on Apeiron RIA's 13F filing for Q3 2022, filed 18 Oct 2022.